4-{[4-(4-{2-[2-(methylsulfonyl)ethyl]-1H-imidazol-1-yl}butyl)phenoxy]methyl}-2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazole | 511532-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[4-(4-{2-[2-(methylsulfonyl)ethyl]-1H-imidazol-1-yl}butyl)phenoxy]methyl}-2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazole
• 英文别名: 4-[[4-[4-[2-(2-methylsulfonylethyl)imidazol-1-yl]butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
• CAS: 511532-37-9
• 化学式: C₂₉H₃₀F₃N₃O₄S
• 分子量: 573.636
• InChiKey: GQFWQPWZVNORHM-NTEUORMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  95.6
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
  申请人：——

  公开号：US20040242659A1

  公开（公告）日：2004-12-02

  This invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by the formula: 1 wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R 1 is a halogen atom or an optionally halogenated C 1-2 alkyl group; each of R 2 and R 3 is, same or different, a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R 4 is a group represented by the formula: 2 wherein p is an integer of 2 to 5; R 5 is a C 1-4 alkyl group substituted by alkoxycarbonyl group, carbamoyl group, carbamoyloxy group, alkylsulfonyl group, alkylsulfinyl group, sulfamoyl group, carbamoylamino group, alkylsulfonylamino group, acylamino group, and the like; or a salt thereof and a pharmaceutical composition comprising thereof.

  本发明提供了一种具有强大的酪氨酸激酶抑制活性的杂环化合物，其表示为公式1：其中，m为1至3的整数；n为1或2的整数；R1为卤素原子或可选卤代的C1-2烷基；R2和R3中的每一个，相同或不同，为氢原子、卤素原子、低烷基或低烷氧基；R4为公式2所表示的基团：其中p为2至5的整数；R5为被取代的C1-4烷基，取代基为烷氧羰基基团、氨基甲酰基团、氨基甲氧基基团、烷基磺酰基团、烷基亚磺酰基团、磺酰胺基团、氨基甲酰氨基团、烷基磺酰氨基团、酰胺基等；或其盐和含有其的制药组合物。
• HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1439178A1

  公开（公告）日：2004-07-21

  This invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by the formula: wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R1 is a halogen atom or an optionally halogenated C1-2 alkyl group; each of R2 and R3 is, same or different, a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R4 is a group represented by the formula: wherein p is an integer of 2 to 5; R5 is a C1-4 alkyl group substituted by alkoxycarbonyl group, carbamoyl group, carbamoyloxy group, alkylsulfonyl group, alkylsulfinyl group, sulfamoyl group, carbamoylamino group, alkylsulfonylamino group, acylamino group, and the like; or a salt thereof and a pharmaceutical composition comprising thereof.

  本发明提供了一种具有强效酪氨酸激酶抑制活性的杂环化合物，由式表示： 其中m是1至3的整数；n是1或2的整数；R1是卤素原子或任选卤化的C1-2烷基；R2和R3中的每一个相同或不同，是氢原子、卤素原子、低级烷基或低级烷氧基；R4是由式表示的基团： 其中 p 是 2 至 5 的整数；R5 是被烷氧羰基、氨基甲酰基、氨基甲酰氧基、烷基磺酰基、烷基亚磺酰基、氨基磺酰基、氨基甲酰基氨基、烷基磺酰基氨基、酰氨基等取代的 C1-4 烷基；或其盐和包含其的药物组合物。
• FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1644375A2

  公开（公告）日：2006-04-12
• US6984653B2
  申请人：——

  公开号：US6984653B2

  公开（公告）日：2006-01-10
• [EN] FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DERIVES ARYLE ET HETEROARYLE CONDENSES UTILISES COMME MODULATEURS DU METABOLISME ET PROPHYLAXIE ET TRAITEMENT DES TROUBLES METABOLIQUES
  申请人：ARENA PHARM INC

  公开号：WO2005007658A2

  公开（公告）日：2005-01-27

  The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.